CAMBRIDGE, Mass., Aug. 30 /PRNewswire/ -- Xanthus Pharmaceuticals,
Inc., a privately-held oncology drug development company, today announced
that Richard T. Dean, Ph.D., Chief Executive Officer of Xanthus, will
present a corporate overview at the Thomas Weisel Partners Healthcare
Conference 2006 on Wednesday, September 6th at 8:35 am at the Four Seasons
Hotel in Boston. A live audio webcast of the presentation will be available
on the Company's website located at http://www.xanthus.com. A replay of the
presentation will be posted on the Xanthus website approximately thirty
minutes after the event.
About Xanthus Pharmaceuticals, Inc.
Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel,
clinical-stage, small-molecule oncology candidates through a management
team whose accomplished track record encompasses all aspects of drug
development, from discovery through regulatory approval and
commercialization. The Company is applying its expertise both to advance
its current pipeline and expand it into indications of unmet medical need
beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. -
kwatson@macbiocom.com or (508) 647-0209
Lisa Terry, Xanthus Pharmaceuticals, Inc. - lisa.terry@xanthus.com or
(617) 225-0522, x 105
SOURCE Xanthus Pharmaceuticals, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Lisa Terry of Xanthus Pharmaceuticals, Inc.,
+1-617-225-0522, ext. 105, lisa.terry@xanthus.com; or Kari Watson
of MacDougall Biomedical Communications, Inc., +1-508-647-0209,
kwatson@macbiocom.com
|
